Open AccessSeven-year follow-up analysis of adjuvant paclitaxel and trastuzumab trial for node-negative, human epidermal growth factor receptor 2–positive breast cancer
Author(s) -
S.M. Tolaney,
H. Guo,
S. Pernas,
W.T. Barry,
D.A. Dillon,
L. Ritterhouse,
B.P. Schneider,
F. Shen,
K. Fuhrman,
M. Baltay,
C.T. Dang,
D.A. Yardley,
B. Moy,
P.K. Marcom,
K.S. Albain,
H.S. Rugo,
M.J. Ellis,
I. Shapira,
A.C. Wolff,
LA Carey,
B. Overmoyer,
A.H. Partridge,
C.A. Hudis,
I.E. Krop,
H.J. Burstein,
E.P. Winer
Publication year - 2019
Publication title -
carolina digital repository (university of north carolina at chapel hill)
Language(s) - English
DOI - 10.17615/8hhr-k187
Subject(s) - trastuzumab , human epidermal growth factor receptor 2 , paclitaxel , breast cancer , oncology , adjuvant , medicine , epidermal growth factor receptor , cancer research , cancer